Antibody Product
mAb, ADC, RDC, etc.
The production of antibody drugs involves complex processes. From cell line establishment to process scale-up, quality control at each step critically impacts product safety. To ensure antibody drug safety, it is essential to establish rigorous biosafety evaluation systems, employ advanced detection technologies, and continuously optimize quality control strategies.
Biosafety Strategy for Antibody Production
Genetic Stability Testing
The genetic stability and clonality of CHO producer cell lines are closely related to the quality consistency of monoclonal antibody products. BRC Biotech offers comprehensive solutions for cell line development (CLD), clonality, and genetic stability of producer cell line, ensuring stable and consistent product quality.
Regulatory for Genetic Stability Testing

Cell substrate used in biologics production should be evaluated the genetic stability in both master cell bank (MCB) and end of production cell (EOPC) as described in regulatory guidelines, monitoring its genetic locus, coding sequence of the expression cassette or the RNA transcript, the copy number of the transgene. As well, restriction enzyme mapping is suggested to demonstrate integrity and integration pattern of transgene.

Refer to ICHO5D

The genetic stability is recommended in WHO by comparing the profiles in both MCB/WCB and ECB/EOPC. The aspects such as the copy number of GOI (gene of interest), the location of GOI, and the sequences using sanger sequencing should be included.

Refer to WHO TRS 978 / Annex3
Traditional Genetic Stability Testing Methods
Study Item BRC Method
Purity GOI and Flanking Sequencing
RT-qPCR
Genomic Structure Restriction enzyme analysis by Southern Blot
Insert Gene Copy Number qPCR
Transcript Size Northern blot
Cell Line Identity CO1
Karyotype Karyology
GMP-compliant testing system
Full-validated methodology
Completed project management
Meet the quality requirements of biopharmaceuticals
Comply with the international regulations and guidance
Professional regulatory technical support
Genetic Profiling Analysis based on Next Generation Sequencing Technology (NGS)
Recombinant-constructed Chinese hamster ovary cells (CHO) are widely used in the recombinant proteins and therapeutic antibodies production. The construction techniques might lead to off-target effects potentially, However, almost all construction techniques can potentially lead to off-target effects, multiple integration sites, and structural variations in the backbone sequence.


According to ICH 05B and WHO guidelines, it is required to compare the genetic stability between master cell banks (MCBs) and end-of-production cell lines (EOPCs), including the accuracy of coding DNA sequences, insertion site structure stability, and insertion copy number, etc.


Compared with traditional Southern Blotting, FISH and amplicon sequencing, TLA (Targeted Locus Amplification) next generation sequencing technology will bring a new solution for genetic characterization analysis.


BRC is the unique authorized domestic partner of Cergentis 1. Cergentis proprietary TLA-based assays offer clear advantages over standard approaches, most of which are unable to resolve all essential genetic characteristics in one experiment, e.g. as integration mutagenesis or sequence information. Briefly, genomic DNA is crosslinked, fragmented and circular DNA fragments are generated. The locus of interest is amplified and sequenced with NGS technology, and the sequence data are subsequently analyzed.

1: Cergentis is now BRC biotech is Cergentis is Now Solvias NL
Characterization TLA+NGS WGS Amplicon/Capture based qPCR/ddPCR Southern Blot FISH
Integration site × x
Structural variation × × × ×
Convergent integration × × × × ×
Integrate a vector or GOl SNVs × × ×
Indels × × ×
Rearrangement × × × × ×
Tandem × × × ×
Copy number × ×
Feedback to us
* To protect personal privacy, we promise that your personal information will not be provided to third parties! < Privacy Policy >